Article Sidebar

PDF
Date Published: 01/06/2023
Abstract Views: 305
Views PDF: 127
DOI: https://doi.org/10.51298/vmj.v526i2.5494
Issue
Vol. 526 No. 2 (2023)
Section
Các bài báo
How to Cite
Đỗ, H. K. ., & Nguyễn, V. T. . (2023). TREATMENT RESULT OF INDUCTION TCF-REGIMEN CHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIOTHERAPY IN LOCALLY ADVANCED SQUAMOUS CELL HEAD AND NECK CANCER. Vietnam Medical Journal, 526(2). https://doi.org/10.51298/vmj.v526i2.5494

TREATMENT RESULT OF INDUCTION TCF-REGIMEN CHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIOTHERAPY IN LOCALLY ADVANCED SQUAMOUS CELL HEAD AND NECK CANCER

Hùng Kiên Đỗ1,, Văn Tài Nguyễn1
1 k hospital

Main Article Content

Abstract

Objective: Assessing treatment response of induction TCF-regimen chemotherapy followed by concurrent chemoradiotherapy in patients with locally advanced squamous cell head and neck cancer at K Hospital and describing several toxicities of TCF chemotherapy. Patients and method: Retrospective and prospective analysis of 47 patients with locally advanced squamous cell head and neck cancer who were treated with induction TCF-regimen chemotherapy followed by weekly platinum-based concurrent chemoradiotherapy at K Hospital from 01/2019 to 12/2022. Results: Overall response rate was seen in 76.6% and disease control rate was 87.2%. Common hematologic adverse events were neutropenia, accounted for 25% grade 1 and 2,1% grade 3, respectively. The common grades 3-4 non-hematologic toxic effects were diarrhea (4.2%); nausea (12.7%), and vomiting (10.6%). Conclusion: Induction TCF-regimen chemotherapy followed by concurrent chemoradiotherapy for the treatment of locally advanced squamous cell head and neck cancer had a high overall response rate with un acceptable profile of toxicities.

Article Details

Keywords

squamous cell head and neck cancer, locally advanced, induction chemotherapy, TCF

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021, 71, 209–249, doi:10.3322/caac.21660.
2. Nguyễn Văn Hiếu. Ung Thư Học. Nhà xuất bản Y học, 2015.
3. Posner, M.R.; Hershock, D.M.; Blajman, C.R.; Mickiewicz, E.; Winquist, E.; Gorbounova, V.; Tjulandin, S.; Shin, D.M.; Cullen, K.; Ervin, T.J.; et al. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. N Engl J Med 2007, 357, 1705–1715, doi:10.1056/NEJMoa070956.
4. Vermorken, J.B.; Remenar, E.; van Herpen, C.; Gorlia, T.; Mesia, R.; Degardin, M.; Stewart, J.S.; Jelic, S.; Betka, J.; Preiss, J.H.; et al. Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer. N Engl J Med 2007, 357, 1695–1704, doi:10.1056/NEJMoa071028.
5. National comprehensive Cancer network (NCCN) NCCN Practice Guideline for Head and Neck Cancer, Version 2022; 2022;
6. Gau, M.; Karabajakian, A.; Reverdy, T.; Neidhardt, E.-M.; Fayette, J. Induction Chemotherapy in Head and Neck Cancers: Results and Controversies. Oral Oncology 2019, 95, 164–169, doi:10.1016/j.oraloncology.2019.06.015.